Published in
Elsevier, The Lancet Oncology, 10(18), p. 1397-1410, 2017
DOI: 10.1016/s1470-2045(17)30622-8
Links
- ORCID
- Elsevier
- ORCID
- [hdl.handle.net]
- [eprints.whiterose.ac.uk] | PDF
- [discovery.ucl.ac.uk] | PDF
- [europepmc.org] | PDF
Tools
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Journal article published in 2017 by
Beatrice Seddon,
Sandra J. Strauss,
Jeremy Whelan,
Michael G. Leahy,
Penella J. Woll 
,
Fiona Cowie,
Christian Rothermundt,
Zoe Wood,
Charlotte Benson,
Nasim Ali,
Maria Marples,
Gareth J. Veal,
David Jamieson ,
Katja Küver,
Roberto Tirabosco
and other authors.
,
Fiona Cowie,
Christian Rothermundt,
Zoe Wood,
Charlotte Benson,
Nasim Ali,
Maria Marples,
Gareth J. Veal,
David Jamieson ,
Katja Küver,
Roberto Tirabosco
and other authors.
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
For many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tissue sarcoma.